Forbes William P, EVP and Chief Development Officer, has engaged in 27 reported transactions across two companies, Heron Therapeutics (HRTX) and Beyond Air (XAIR), according to SEC Form 4 filings. Notably, all transactions recorded a value of $0, indicating they were likely related to equity awards, such as grants, exercises, or dispositions, rather than open-market purchases or sales. The majority of Forbes’ activity is concentrated in HRTX, with 24 transactions spanning from April 2024 through January 2026. These include multiple instances of code "M" (disposition to issuer) and "A" (award or grant), reflecting routine equity-related actions.
Forbes’ involvement with XAIR is limited to a single day, November 4, 2025, with 11 transactions marked by alternating codes "A" and "D" (sale back to issuer). This pattern suggests a structured equity event, possibly related to vesting or forfeiture of awards. Despite the volume of transactions, there is no evidence of open-market buying or selling, as all reported values remain at $0. This activity aligns with typical executive equity management practices, focusing on equity awards rather than discretionary trading. The data underscores Forbes’ consistent engagement with equity compensation mechanisms at HRTX and a brief, structured interaction with XAIR.
AI-assisted summary